Evrys Bio
- Biotech or pharma, therapeutic R&D
- Biotech or pharma, animal health
Evrys Bio breakthrough SIRT2 modulator platform has generated a range of broad spectrum anti-viral compounds that target host cell molecular targets. Each molecule, including our late preclinical EV-100 is effective against a range of high impact viruses (including RSV, Infl.A, B, etc.), and also some bacteria. The host targeted mechanism helps overcome resistance. Initial targets are respiratory diseases, hepatitis, opportunistic transplantation infections and pandemic preparedness. The mechanism has applicability to other disease areas including Cancer, Immunology, etc.
EV-100 is our successful pre-IND small molecule, with the initial target indication of CMV transplant, with opportunities of expansion into additional indications. Various other compounds and tool compounds available for testing. We are looking for investors & pharmaceutical research collaboration partners.
Lillian Chiang, PhD, MBA; CEO & Robert Besthof, MIM; COO are attending.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}